Lyra Therapeutics reports Q3 net loss $6.0M, plans new Phase 3 trial for LYR-210

Lyra Therapeutics, Inc.

2025-Q3 EPS reported -$14.85 revenue$391,000

Cash and cash equivalents $22.1M at Sep 30, 2025; cash runway into Q3 2026.
Net loss for Q3 2025 was $6.0M, down from $11.9M in Q3 2024.
R&D expenses decreased 32% to $4.0M; G&A decreased 43% to $2.2M due to cost reductions.
Planning confirmatory Phase 3 trial of LYR-210 for CRS without nasal polyps following FDA meeting.
Presented positive ENLIGHTEN 2 Phase 3 results at AAO-HNS meeting in October 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.